FDA's Opioid REMS Proposal Has Narrow Focus On Education
Executive Summary
Faced with data gaps, inadequate metrics and the need to maintain access to therapies, FDA takes a narrow approach to addressing long-acting and extended-release opioid abuse and misuse in its proposed Risk Evaluation and Mitigation Strategy for the painkillers
You may also be interested in...
Does Mandatory Opioid Prescriber Education Go Far Enough? Congress Might Say No
Congress and FDA already are sparring over the drug companies’ mandate to pay for the prescriber education included in the national prescription drug abuse plan.
Does Mandatory Opioid Prescriber Education Go Far Enough? Congress Might Say No
Congress and FDA already are sparring over the drug companies’ mandate to pay for the prescriber education included in the national prescription drug abuse plan.
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.